Timothy A. Yap, MD, PhD, on New Findings on Treating Solid Tumors With PARP and ATR Inhibitors

AACR Annual Meeting 2023


Timothy A. Yap, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses safety and efficacy data on three different PARP inhibitors combined with the ATR inhibitor camonsertib in patients with solid tumors harboring DNA damage response alterations. The findings showed that low-dose intermittent regimens of camonsertib and different PARP inhibitor combinations were safe. In addition, anticancer activity was observed in patients with platinum- and PARP inhibitor–resistant tumors. Patients with late-line ovarian cancer derived the most benefit from therapy. (Abstract CT018)


Disclaimer: This video transcript has not been proofread or edited and may contain errors.
We now have four FDA-approved PARP inhibitors for various indications in patients with different cancers. This has really made a huge difference to patients lives. However, even in the most sensitive of patients, for example, patients with BRCA 1 and BRCA 2 mutated cancers, not all patients will respond. In addition to that, even in patients who respond, the chances of resistance coming in, leading to resistance and disease progression is still a near inevitable consequence, and therefore we really need better treatment options for patients. And a rational approach is really to try and develop combinations that make sense to the biology of the cancer as it evolves over time. So, with that in mind, in this clinical trial that I presented, we combined the ATR inhibitor camonsertib with three different PARP inhibitors, olaparib, talazoparib, and niraparib, to try and optimize the use of this combination in terms of a therapeutic window that is well tolerated, but would also lead to efficacy. In the past, the concomitant combinations of high doses of these drugs has led to overwhelming toxicities in patients because of overlapping toxicities, including myelosuppression, fatigue and GI symptoms. So, on this clinical trial, we use low dose intermittent regimens of the ATR inhibitor, camonsertib, and the three different PARP inhibitors in combination. And we found that this was safe and well-tolerated in patients. There were hematological events observed, but these were transient and reversible with dose interruptions. No prophylactic growth factors were required on trial. Importantly, antitumor activity was observed in patients with platinum and PARP inhibitor resistant tumors with predefined DDR genomic alterations. And the durable antitumor activity was encouraging with a clinical benefit rate of 48% in the efficacy population of 90 patients. And in patients with late-line ovarian cancer, which is a real area of clinical unmet need, they derive the most benefit from therapy with an overall response of 32%, a clinical benefit rate of 58%, and a median progression-free survival of approximately seven months, which really compares favorably to current therapeutic options for patients. The molecular response rate as well was 66% in 47 evaluable patients, really supporting the antitumor activity of the combinations. Currently, dose optimization to refine a tailored [inaudible 00:03:03] dose and tumor-specific expansions is ongoing in this clinical trial. But this approach could certainly represent a novel strategy and patients who have great unmet need and really truly represents an area of unmet clinical need.

Related Videos

Hepatobiliary Cancer

Pierce K.H. Chow, PhD, MBBS, on Hepatocellular Carcinoma: New Data From the IMbrave050 Trial of Atezolizumab, Bevacizumab, and Active Surveillance

Pierce K.H. Chow, PhD, MBBS, of the National Cancer Centre, Singapore and Duke-NUS Medical School, discusses phase III findings showing that, for patients with hepatocellular carcinoma at high risk of disease recurrence, adjuvant therapy with atezolizumab plus bevacizumab after resection or thermal ablation was more effective than active surveillance. According to Dr. Chow, these results could lead to reassessment of surgical resection in this disease. (Abstract CT003)


Dario A. Vignali, PhD, on LAG3: The Third Checkpoint Inhibitor

Dario A. Vignali, PhD, of the University of Pittsburgh School of Medicine, discusses LAG3, the third inhibitory receptor to be used in the clinic. He describes the signaling mechanism this immunotherapy uses; new insight into its function, alone and in combination with PD-1; and an analysis of samples from patients treated with LAG3/PD-1 therapeutics. (Abstract PL04-05)

Skin Cancer

Jeffrey S. Weber, MD, PhD, on Melanoma: New Data on a Cancer Vaccine Combined With Pembrolizumab

Jeffrey S. Weber, MD, PhD, of the Perlmutter Cancer Center at New York University Langone, discusses efficacy and safety results from the phase II KEYNOTE-942 trial, which showed that a personalized mRNA-based cancer vaccine, combined with the immune checkpoint inhibitor pembrolizumab, improved recurrence-free survival compared with pembrolizumab alone in patients with high-risk melanoma. The clinical benefit was observed regardless of the tumor mutational burden status. (Abstract CT001)

Hepatobiliary Cancer

R. Katie Kelley, MD, on Biliary Tract Cancer: Data From KEYNOTE-966 on Pembrolizumab, Gemcitabine, and Cisplatin

R. Katie Kelley, MD, of the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, discusses phase III findings of the KEYNOTE-966 study, which showed that adding the immune checkpoint inhibitor pembrolizumab to gemcitabine and cisplatin improved overall survival in patients with untreated metastatic or unresectable biliary tract cancer. (Abstract CT008)

Lung Cancer

John V. Heymach, MD, PhD, on NSCLC: New Data on Durvalumab Plus Chemotherapy From the AEGEAN Trial

John V. Heymach, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase III results from the AEGEAN trial, which showed that patients with treatment-naive, resectable, non–small cell lung cancer (NSCLC) who received neoadjuvant durvalumab plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival and pathologic complete response, compared with those who received neoadjuvant chemotherapy alone. (Abstract CT005)